OVERVIEW

11th Annual Oligonucleotides, mRNA & Peptide Therapeutics (OPT) Congress is organized by Cambridge Healthtech Institute (CHI) and will be held from Mar 18 - 19, 2026 at Seaport Hotel Boston, Boston, Massachusetts, United States of America.

Description:
OPT Congress 2026 is the leading industry event for scientists, directors, and technology providers driving innovation across oligonucleotide, mRNA, and peptide therapeutics. Now in its 11th year, this event provides a unique forum for translating cutting-edge science into transformative medicines, with expanded 2026 programming that includes the brand-new Peptides & Emerging Drug Conjugates conference. This year’s agenda brings together experts from discovery through development, with dedicated content spanning AI-enabled design, extrahepatic delivery, scalable manufacturing, and next-gen modalities including saRNA, circular RNA, and radioligand peptide conjugates.

Across four focused conferences —Oligonucleotide Discovery & Delivery, CMC & Manufacturing, mRNA & Emerging Modalities, and Peptides & Emerging Conjugates—attendees will explore 60+ scientific presentations, collaborative case studies, and real-world implementation strategies. From novel linkers and chemistries to regulatory insights, tech transfer, and delivery breakthroughs, OPT Congress fosters dialogue between pharma, biotech, academia, and technology providers. Join us for two days of actionable insights, short courses, and customizable content designed to support your therapeutic programs from bench to bedside.

Advancing Discovery & Development in Oligonucleotides, mRNA & Peptides